A detailed history of Ubs Group Ag transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 92,001 shares of TSHA stock, worth $184,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,001
Previous 56,079 64.06%
Holding current value
$184,922
Previous $125,000 47.2%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.01 - $2.46 $72,203 - $88,368
35,922 Added 64.06%
92,001 $184,000
Q2 2024

Aug 13, 2024

SELL
$2.04 - $4.17 $271,738 - $555,464
-133,205 Reduced 70.37%
56,079 $125,000
Q1 2024

May 13, 2024

BUY
$1.43 - $3.25 $265,037 - $602,358
185,341 Added 4700.51%
189,284 $543,000
Q4 2023

Feb 09, 2024

BUY
$1.33 - $2.88 $4,512 - $9,771
3,393 Added 616.91%
3,943 $6,000
Q3 2023

Nov 09, 2023

SELL
$0.63 - $3.66 $4,636 - $26,933
-7,359 Reduced 93.05%
550 $1,000
Q2 2023

Aug 11, 2023

BUY
$0.59 - $0.87 $2,571 - $3,792
4,359 Added 122.79%
7,909 $5,000
Q1 2023

May 12, 2023

SELL
$0.65 - $2.3 $128,884 - $456,053
-198,284 Reduced 98.24%
3,550 $2,000
Q4 2022

Feb 08, 2023

BUY
$1.39 - $2.98 $271,831 - $582,774
195,562 Added 3118.02%
201,834 $456,000
Q3 2022

Nov 10, 2022

SELL
$1.76 - $4.94 $155,386 - $436,142
-88,288 Reduced 93.37%
6,272 $12,000
Q2 2022

Aug 10, 2022

BUY
$2.47 - $6.77 $65,652 - $179,946
26,580 Added 39.1%
94,560 $352,000
Q1 2022

May 16, 2022

BUY
$5.22 - $11.86 $88,447 - $200,955
16,944 Added 33.2%
67,980 $443,000
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $201,773 - $338,937
17,653 Added 52.88%
51,036 $594,000
Q3 2021

Nov 15, 2021

BUY
$15.82 - $21.57 $444,273 - $605,750
28,083 Added 529.87%
33,383 $622,000
Q2 2021

Aug 13, 2021

SELL
$19.29 - $26.38 $596,273 - $815,432
-30,911 Reduced 85.36%
5,300 $112,000
Q1 2021

May 12, 2021

BUY
$20.3 - $31.75 $9,378 - $14,668
462 Added 1.29%
36,211 $735,000
Q4 2020

Feb 11, 2021

BUY
$19.14 - $28.13 $473,695 - $696,189
24,749 Added 224.99%
35,749 $949,000
Q3 2020

Nov 12, 2020

BUY
$22.4 - $24.47 $246,399 - $269,170
11,000 New
11,000 $247,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $97.2M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.